Nataliya Mar
Overview
Explore the profile of Nataliya Mar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Powles T, Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al.
Future Oncol
. 2025 Jan;
21(7):749-764.
PMID: 39889805
No abstract available.
2.
Benjamin D, Kalebasty A, Mar N
Eur Urol Oncol
. 2025 Jan;
PMID: 39855979
The recent withdrawal of sacituzumab govitecan for advanced urothelial carcinoma has revealed several implications, including concerns over a lack of remaining effective treatment options, reimbursement, supportive care measures (such as...
3.
Harada G, Seyedin S, Heutlinger O, Azizi A, Hsu A, Rezazadeh A, et al.
Adv Radiat Oncol
. 2024 Dec;
10(1):101671.
PMID: 39655154
Purpose: Pelvic lymph node metastases (ypN+) after multiagent neoadjuvant chemotherapy (NAC) is a poor prognostic sign in nonmetastatic muscle-invasive bladder cancer (nmMIBC). We sought to create a nomogram predicting probability...
4.
Sheybaee Moghaddam F, Dwabe S, Mar N, Safdari L, Sabharwal N, Goldberg H, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409980
Radical cystectomy with lymph node dissection and urinary diversion is the gold-standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC). However, in patients who refuse cystectomy, or in whom cystectomy carries...
5.
Heutlinger O, Azizi A, Harada G, Harris J, Daneshvar M, Gin G, et al.
Cureus
. 2024 Oct;
16(9):e68945.
PMID: 39381448
Purpose This study aimed to identify factors associated with delays in initiating early salvage radiation therapy in prostate cancer patients with prostate-specific antigen (PSA) failure after prostatectomy. Methods We conducted...
6.
Seyedin S, Harada G, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, et al.
Cureus
. 2024 Aug;
16(7):e64781.
PMID: 39156348
Papillary renal cell carcinoma (pRCC) is a rare kidney cancer with limited treatment options and poor outcomes when metastatic. We present a case of a 42-year-old male with metastatic pRCC...
7.
Yu E, Ferrario C, Linch M, Stoeckle M, Laguerre B, Arranz J, et al.
Eur Urol Oncol
. 2024 Jun;
PMID: 38926066
Background And Objective: Abiraterone acetate (abiraterone) plus prednisone is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our aim was to evaluate the efficacy and safety of pembrolizumab...
8.
Powles T, Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al.
N Engl J Med
. 2024 Mar;
390(10):875-888.
PMID: 38446675
Background: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Methods: We conducted a phase 3, global, open-label,...
9.
Benjamin D, Arter Z, Mar N, Kalebasty A
Nat Rev Urol
. 2024 Mar;
21(7):385-386.
PMID: 38429488
No abstract available.
10.
Milowsky M, ODonnell P, Hoimes C, Petrylak D, Flaig T, Moon H, et al.
J Clin Oncol
. 2024 Jan;
42(12):1403-1414.
PMID: 38215355
Purpose: Locally advanced/metastatic urothelial cancer (la/mUC) affects patients' quality of life (QOL) and functioning. We describe the impact of first-line (1L) enfortumab vedotin (EV) alone or with pembrolizumab (P) on...